NCT05177042 - Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

July 2, 2024

Study Completion Date

April 10, 2025

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

ARV-110 in Combination with Abiraterone

ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles

Trial Locations (18)

22903

Clinical Trial Site, Charlottesville

29572

Clinical Trial Site, Myrtle Beach

33916

Clinical Trial Site, Fort Myers

37203

Clinical Trial Site, Nashville

43210

Clinical Trial Site, Columbus

91361

Clinical Trial Site, Santa Monica

97239

Clinical Trial Site, Portland

06519

Clinical Trial Site, New Haven

02114

Clinical Trial Site, Boston

Unknown

Clinical Trial Site, Vancouver

Clinical Trial Site, Toronto

Clinical Trial Site, Montreal

Clinical Trial Site, Caen

Clinical Trial Site, Paris

Clinical Trial Site, Villejuif

Clinical Trial Site, London

Clinical Trial Site, Cardiff

PR2 9HT

Clinical Trial Site, Preston

All Listed Sponsors

lead

Arvinas Androgen Receptor, Inc.

INDUSTRY